Xeligekimab Achieves Sustained Joint and Skin Improvement in Psoriatic Arthritis: A Real-World Subgroup Analysis from a Prospective, Multicenter, Observational Study in China (XP-Real) (EADV 2026) - Aug 6, 2026 - Abstract #P1171; AS-2020; Pres time: Sep 30, 2026; Location: ePoster Area; P | "(C-G) Mean change from baseline in joint counts over 24 weeks: (C) tender joint count (TJC68), (D) tender joint count (TJC28), (E) swollen joint count (SJC66), (F) swollen joint count (SJC28), (G) entheseal tender joint count (TJC6). (H) Mean change from baseline in patient disease activity VAS."
Clinical • Observational data • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A
|
|
Yehong Kuang 1; Wenjun Zheng 2; Xincai Xiong 3; Nan Yu 4; Yong Zhang 5; LAN CHEN 5; Yunfeng Hu 6; Yanhua Liang 7; Cuihong Lian 8; Naihui Zhou 9; Furen Zhang 10; Yu Gong 11; Rui-Li Zhang 12; Na Zhang 13; Juan Su 1; Xiang Chen 1
|